Carterra® is a leading provider of innovative technologies designed to accelerate the discovery of novel large and small molecule therapeutic candidates, enabling faster medicines to patients. Carterra’s high throughput screening and characterization technology combines patented microfluidics with real-time High Throughput Surface Plasmon Resonance (HT-SPR) instruments, consumables, and industry-leading Kinetic and Epitope Analysis and Visualization Software™, delivering up to 100 times the throughput in 10% of the time while using only 1% of the sample compared to existing platforms. Carterra technology condenses months of work into a few days.
Read about Carterra in the news:
- Carterra Launches Industry’s First 48-channel HT-SPR Platform for Advanced Label-free Biomolecular Screening and Characterization
- Carterra Ships Its First Ultra Biosensor Platform and Finishes 2024 with Double-digit Growth and Record Revenues
- Vanderbilt University School of Medicine Basic Sciences Adds Carterra’s LSAXT Instrument to Speed Drug and Vaccine Research and Advance Patient Care
- Carterra unveils its most sensitive biosensor platform; Carterra Ultra™ ushers in a new frontier in fragment and small molecule drug discovery
- Standard BioTools Purchases the Carterra® LSAXT System to Accelerate Data Delivery and Provide Greater Validation to SomaScan® Customers
- IPA Acquires the Carterra LSA® Instrument to Enhance Antibody Discovery and Bolster Its AI Developments
- Ordaōs Acquires the Carterra®LSA® Platform to Further Speed and Optimize Its Machine-Driven Drug Design System
- More News